SCYX News and Press, SCYNEXIS Inc.

2024-05-31 11:50:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting s...

2024-05-23 06:42:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate ...

2024-05-08 17:40:51 ET More on SCYNEXIS Scynexis: Update Following Restructuring Of GSK Deal Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS Financial information for SCYNEXIS Read the full article on Seeking Al...

SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would...

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...

JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-genera...

2024-04-02 10:04:00 ET Summary Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years...

2024-03-28 16:59:01 ET More on SCYNEXIS GSK revises Scynexis licensing deal for antifungal agent Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS Financial information for SCYNEXIS Read the full article on Seekin...

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results...

JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will pre...